U.S. FDA Approves INVOKANA ® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news